BTIG Research downgraded shares of MacroGenics (NASDAQ:MGNX – Free Report) from a buy rating to a neutral rating in a research note released on Thursday morning, MarketBeat reports.
Several other research analysts have also recently weighed in on the stock. Barclays lowered their price target on shares of MacroGenics from $14.00 to $9.00 and set an overweight rating on the stock in a report on Monday, July 29th. HC Wainwright reduced their price target on MacroGenics from $16.00 to $4.00 and set a neutral rating for the company in a research note on Monday, May 13th. Stifel Nicolaus downgraded MacroGenics from a buy rating to a hold rating and dropped their target price for the stock from $29.00 to $7.00 in a report on Friday, May 10th. Guggenheim downgraded shares of MacroGenics from a buy rating to a neutral rating in a research note on Wednesday, July 31st. Finally, BMO Capital Markets lowered shares of MacroGenics from an outperform rating to a market perform rating and decreased their target price for the stock from $24.00 to $8.00 in a research report on Friday, May 10th. Eight analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, MacroGenics presently has a consensus rating of Hold and an average price target of $8.33.
Get Our Latest Report on MacroGenics
MacroGenics Trading Down 10.4 %
MacroGenics (NASDAQ:MGNX – Get Free Report) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.17). The firm had revenue of $9.10 million during the quarter, compared to the consensus estimate of $13.63 million. MacroGenics had a negative net margin of 53.60% and a negative return on equity of 98.01%. As a group, analysts expect that MacroGenics will post -2.19 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. EntryPoint Capital LLC bought a new position in MacroGenics during the 1st quarter valued at $40,000. CANADA LIFE ASSURANCE Co purchased a new position in MacroGenics during the first quarter worth about $52,000. Sound Income Strategies LLC bought a new stake in MacroGenics in the 1st quarter worth about $77,000. AJOVista LLC purchased a new stake in MacroGenics in the 4th quarter valued at about $51,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of MacroGenics by 349.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,174 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 5,577 shares in the last quarter. 96.89% of the stock is owned by institutional investors.
About MacroGenics
MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
See Also
- Five stocks we like better than MacroGenics
- Manufacturing Stocks Investing
- PulteGroup is Buying Back $1.5 Billion in Stock During a Crash
- Business Services Stocks Investing
- Why a Recession is Back in Play and What it Means for Stocks
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Defensive Stocks Weathering the Market Storm
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.